期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 102, 期 1, 页码 20-35出版社
WILEY
DOI: 10.1111/ejh.13172
关键词
acute myeloid leukemia; molecular markers; prognostic impact
类别
资金
- Olympia-Morata program from the Medical Faculty of the Heidelberg University
- NCI (NCI Leukemia SPORE) [P50 CA100632]
The recently updated World Health Organization (WHO) Classification of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, particularly the large subset of cytogenetically normal AML. Despite the progress in unraveling the tumor genome, only a small number of recurrent mutations have been incorporated into risk-stratification schemes and have been proven to be clinically relevant, targetable lesions. We here discuss the utility of molecular markers in AML in prognostication and treatment decision making, specifically highlighting the aberrations included in the current WHO classification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据